Recommendations in NICE’s type 2 diabetes guideline update, published today, will enhance the use of SGLT-2 inhibitors in primary care and address these health inequalities.
People with heart disease will be able to do their recovery sessions from home rather than travelling for rehabilitation appointments after our independent committee conditionally recommended 6 digital platforms for use in the NHS.
In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid lipofuscinosis type 2 (CLN2), a rare and life-limiting form of Batten disease.
NICE recommends idebenone for Leber's hereditary optic neuropathy following clinical evidence of vision improvement.
NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.
Around 2,100 people with advanced womb cancer are set to benefit from a groundbreaking new treatment option, following our recommendation of pembrolizumab (Keytruda) in final draft guidance published today.
Page 2 of 41